Table 3.
Aspartate Transaminase (AST) and Alanine Transaminase (ALT) measurements in a phase I study of sildenafil in premature infants.
| Cohort 1 (n = 25) Multiple doses | Cohort 2 (n = 9) Single IV dose | ||
|---|---|---|---|
| Dose group 0.25 mg/kg (n = 7) | Dose group 0.125 mg/kg (n = 2) | ||
| AST (U/L), Median (Min, Max) | |||
| Baseline AST | 36 (17, 59) | 34 (14, 120) | 53.5 (49, 58) |
| Follow-up AST | 35 (19, 237) | 26 (13, 175) | 30 (23, 37) |
| Change from baseline to follow-up AST | −2 (−16, 209) | 1 (−19, 55) | −23.5 (−26, −21) |
| ALT (U/L), Median (Min, Max) | |||
| Baseline ALT | 18 (7, 54) | 24 (4, 108) | 12.5 (11, 14) |
| Follow-up ALT | 16.5 (8, 161) | 14 (5, 156) | 9.5 (9, 10) |
| Change from baseline to follow-up ALT | 1.5 (−22, 146) | 1 (−10, 86) | −3 (−5, −1) |
AST aspartate transaminase, ALT alanine transaminase, IV intravenous, mg milligrams kg, kilograms, U/L units per liter.